This is in line with the fact that, despite drugs targeting the BAFF/APRIL system such as atacicept have been adopted for the treatment of other autoimmune disorders, to date they provided unsatisfactory results in MS [125]. Here, TNFSF13 is linked to myeloid sarcoma.